SEARCH

SEARCH BY CITATION

Keywords:

  • respiratory syncytial virus;
  • monoclonal antibody;
  • palivizumab;
  • randomized controlled trial;
  • cost-effectiveness

Abstract

Cochrane Review: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD006602. DOI: 10.1002/14651858.CD006602.pub4

This companion piece to the review, “Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children,” contains the following pieces:

  • The abstract of the review

  • A commentary from one or more of the review authors, explaining why the review team felt the review was an important one to produce

  • A review of clinical practice guidelines from the American Academy of Pediatrics, the Canadian Paediatric Society and the National Institute for Health and Care Excellence (NICE), United Kingdom

  • Some other recently published references on this topic